{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:31:14Z","timestamp":1792513874387,"version":"4.5.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    (\n                    <jats:italic>H. pylori<\/jats:italic>\n                    ) have infected about 50% of the world\u2019s population and is a leading cause of gastrointestinal diseases, including gastritis, peptic ulcer, and stomach cancer. Current treatment regimens often fail to completely eradicate the bacteria due to the failure of antibiotics to penetrate into stomach\u2019s inner mucosa, where the bacteria reside. Additional factors such as the ability of the organism to neutralize the stomach\u2019s acidic environment and biofilm formation further contribute to treatment failure leading to antibiotic resistance. These challenges underscore the urgent need for new treatment options and strategies to combat\n                    <jats:italic>H. pylori<\/jats:italic>\n                    effectively. The current review delivers an overview of the pathophysiology of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    , the limitations of the current regimens, and the potential of nanoemulsion as a smart carrier addressing the limitations associated with\n                    <jats:italic>H. pylori<\/jats:italic>\n                    treatment. The nanoemulsion offers specific advantages like mucoadhesion potential, targeted delivery, controlled release, and co-delivery options that ultimately results in an enhancement of bioavailability of the antibiotics to\n                    <jats:italic>H. pylori<\/jats:italic>\n                    , which resides in the inner walls of the stomach mucosa. Further, the ability of nanoemulsions to encapsulate the drug molecules helps in protecting the antibiotics from the stomach acidity facilitating drug stability. In conclusion, the review highlights the importance of tapping this unexplored potential of nanoemulsion as a promising drug delivery option for the treatment of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-025-01986-7","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:27:33Z","timestamp":1760372853000},"page":"17-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nanoemulsion as a promising drug delivery strategy for effective eradication of Helicobacter pylori: current insights"],"prefix":"10.1007","volume":"16","author":[{"given":"Moumita","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Kunkalienkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namdev","family":"Dhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandakumar","family":"Krishnadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalakshmi","family":"Narasimhaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-0981","authenticated-orcid":false,"given":"Sudheer","family":"Moorkoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1986_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/diseases9040066","volume":"9","author":"M \u00d6ztekin","year":"2021","unstructured":"\u00d6ztekin M, Y\u0131lmaz B, A\u011fag\u00fcnd\u00fcz D, Capasso R. Overview of Helicobacter pylori infection: clinical Features, Treatment, and nutritional aspects. Diseases. 2021;9:66.","journal-title":"Diseases"},{"key":"1986_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, Liou J-M, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primer. 2023;9:1\u201324.","journal-title":"Nat Rev Dis Primer"},{"key":"1986_CR3","unstructured":"15th Report on Carcinogens [Internet]. Natl. Toxicol. Program. 2021 [cited 2024 Jan 31]. Available from: https:\/\/ntp.niehs.nih.gov\/whatwestudy\/assessments\/cancer\/roc"},{"key":"1986_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00054-05","volume":"19","author":"JG Kusters","year":"2006","unstructured":"Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449\u201390.","journal-title":"Clin Microbiol Rev"},{"key":"1986_CR5","unstructured":"Azer SA, Awosika AO, Akhondi H. Gastritis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544250\/"},{"key":"1986_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40792-020-01081-8","volume":"7","author":"T Yokoyama","year":"2021","unstructured":"Yokoyama T, Tanaka T, Harada S, Ueda T, Ejiri G, Sasaki S, et al. A case of gastric and duodenal mucosa-associated lymphoid tissue lymphoma with multiple gastric cancers: a case report. Surg Case Rep. 2021;7:30.","journal-title":"Surg Case Rep"},{"key":"1986_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/jcm8020179","volume":"8","author":"L Kuna","year":"2019","unstructured":"Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options. J Clin Med. 2019;8:179.","journal-title":"J Clin Med"},{"key":"1986_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/CMR.00011-10","volume":"23","author":"LE Wroblewski","year":"2010","unstructured":"Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713\u201339.","journal-title":"Clin Microbiol Rev"},{"key":"1986_CR9","doi-asserted-by":"publisher","first-page":"31146","DOI":"10.18632\/oncotarget.25757","volume":"9","author":"M Pucu\u0142ek","year":"2018","unstructured":"Pucu\u0142ek M, Machlowska J, Wierzbicki R, Baj J, Maciejewski R, Sitarz R. Helicobacter pylori associated factors in the development of gastric cancer with special reference to the early-onset subtype. Oncotarget. 2018;9:31146\u201362.","journal-title":"Oncotarget"},{"key":"1986_CR10","unstructured":"Asaka M, Sepulveda AR, Sugiyama T, Graham DY. Gastric Cancer. In: Mobley HL, Mendz GL, Hazell SL, editors. Helicobacter Pylori Physiol Genet [Internet]. Washington (DC): ASM Press; 2001 [cited 2024 Oct 7]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2445\/"},{"key":"1986_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12929-018-0469-6","volume":"25","author":"F-W Tsay","year":"2018","unstructured":"Tsay F-W. Hsu P-I. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018;25:65.","journal-title":"J Biomed Sci"},{"key":"1986_CR12","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3748\/wjg.v24.i29.3204","volume":"24","author":"AG Gravina","year":"2018","unstructured":"Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018;24:3204\u201321.","journal-title":"World J Gastroenterol"},{"key":"1986_CR13","first-page":"219","volume":"115","author":"M Narayanan","year":"2018","unstructured":"Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115:219\u201324.","journal-title":"Mo Med"},{"key":"1986_CR14","first-page":"8","volume":"31","author":"SA Polyzos","year":"2018","unstructured":"Polyzos SA, Zeglinas C, Artemaki F, Doulberis M, Kazakos E, Katsinelos P, et al. Helicobacter pylori infection and esophageal adenocarcinoma: a review and a personal view. Ann Gastroenterol. 2018;31:8\u201313.","journal-title":"Ann Gastroenterol"},{"key":"1986_CR15","doi-asserted-by":"crossref","unstructured":"Wang L, Cao Z-M, Zhang L-L, Dai X, Liu Z, Zeng Y et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol [Internet]. 2022 [cited 2024 Feb 1];13. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8866759\/","DOI":"10.3389\/fimmu.2022.833424"},{"key":"1986_CR16","first-page":"72","volume":"89","author":"K Stefano","year":"2018","unstructured":"Stefano K, Marco M, Federica G, Laura B, Barbara B, Gioacchino L, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the Art. Acta Bio Med Atenei Parm. 2018;89:72\u20136.","journal-title":"Acta Bio Med Atenei Parm"},{"key":"1986_CR17","unstructured":"Helicobacter pylori | CDC Yellow. Book 2024 [Internet]. [cited 2024 Feb 1]. Available from: https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/infections-diseases\/helicobacter-pylori"},{"key":"1986_CR18","unstructured":"Awochna. H. Pylori Transmission and Spread of Infection [Internet]. 2014 [cited 2024 Feb 1]. Available from: https:\/\/publichealth.arizona.edu\/outreach\/health-literacy-awareness\/hpylori\/transmission"},{"key":"1986_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/oxfordjournals.epirev.a018040","volume":"22","author":"LM Brown","year":"2000","unstructured":"Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22:283\u201397.","journal-title":"Epidemiol Rev"},{"key":"1986_CR20","first-page":"146","volume":"8","author":"M Zamani","year":"2017","unstructured":"Zamani M, Vahedi A, Maghdouri Z, Shokri-Shirvani J. Role of food in environmental transmission of Helicobacter pylori. Casp J Intern Med. 2017;8:146\u201352.","journal-title":"Casp J Intern Med"},{"key":"1986_CR21","doi-asserted-by":"publisher","first-page":"e9082716","DOI":"10.1155\/2017\/9082716","volume":"2017","author":"O Amaral","year":"2017","unstructured":"Amaral O, Fernandes I, Veiga N, Pereira C, Chaves C, Nelas P, et al. Living conditions and Helicobacter pylori in adults. BioMed Res Int. 2017;2017:e9082716.","journal-title":"BioMed Res Int"},{"key":"1986_CR22","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.3390\/nu14194215","volume":"14","author":"F Habbash","year":"2022","unstructured":"Habbash F, Alalwan TA, Perna S, Ahmed N, Sharif O, Al Sayyad A, et al. Association between dietary habits and Helicobacter pylori infection among Bahraini adults. Nutrients. 2022;14:4215.","journal-title":"Nutrients"},{"key":"1986_CR23","unstructured":"Helicobacter Pylori Infections Treatment Market Size \u2013\u20092033 | FMI [Internet]. [cited 2024 Sep 17]. Available from: https:\/\/www.futuremarketinsights.com\/reports\/helicobacter-pylori-infections-treatment-market"},{"key":"1986_CR24","doi-asserted-by":"publisher","first-page":"e0294403","DOI":"10.1371\/journal.pone.0294403","volume":"18","author":"N Aumpan","year":"2023","unstructured":"Aumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone R. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS ONE. 2023;18:e0294403.","journal-title":"PLoS ONE"},{"key":"1986_CR25","doi-asserted-by":"publisher","first-page":"e20406","DOI":"10.1016\/j.heliyon.2023.e20406","volume":"9","author":"A Gupta","year":"2023","unstructured":"Gupta A, Shetty S, Mutalik S, Chandrashekar HR, Mathew KN. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023;9:e20406.","journal-title":"Heliyon"},{"key":"1986_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics9080436","volume":"9","author":"SY Kim","year":"2020","unstructured":"Kim SY, Chung J-W. Best Helicobacter pylori eradication strategy in the era of antibiotic resistance. Antibiotics. 2020;9:436.","journal-title":"Antibiotics"},{"key":"1986_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells10010027","volume":"10","author":"J Baj","year":"2020","unstructured":"Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, et al. Helicobacter pylori virulence Factors\u2014Mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2020;10:27.","journal-title":"Cells"},{"key":"1986_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bj.2015.06.002","volume":"39","author":"C-Y Kao","year":"2016","unstructured":"Kao C-Y, Sheu B-S, Wu J-J. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14\u201323.","journal-title":"Biomed J"},{"key":"1986_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s42770-021-00675-0","volume":"53","author":"HC Sharndama","year":"2022","unstructured":"Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53:33\u201350.","journal-title":"Braz J Microbiol"},{"key":"1986_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12929-018-0466-9","volume":"25","author":"W-L Chang","year":"2018","unstructured":"Chang W-L, Yeh Y-C, Sheu B-S. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci. 2018;25:68.","journal-title":"J Biomed Sci"},{"key":"1986_CR31","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.3390\/jcm11113141","volume":"11","author":"S Ansari","year":"2022","unstructured":"Ansari S, Yamaoka Y. Animal models and Helicobacter pylori infection. J Clin Med. 2022;11:3141.","journal-title":"J Clin Med"},{"key":"1986_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fcimb.2012.00092","volume":"2","author":"SL Palframan","year":"2012","unstructured":"Palframan SL, Kwok T, Gabriel K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol. 2012;2:92.","journal-title":"Front Cell Infect Microbiol"},{"key":"1986_CR33","doi-asserted-by":"publisher","first-page":"12753","DOI":"10.3748\/wjg.v20.i36.12753","volume":"20","author":"TT Lina","year":"2014","unstructured":"Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol. 2014;20:12753\u201366.","journal-title":"World J Gastroenterol"},{"key":"1986_CR34","doi-asserted-by":"publisher","first-page":"868225","DOI":"10.3389\/fimmu.2022.868225","volume":"13","author":"D Sijmons","year":"2022","unstructured":"Sijmons D, Guy AJ, Walduck AK, Ramsland PA. Helicobacter pylori and the role of lipopolysaccharide variation in innate immune evasion. Front Immunol. 2022;13:868225.","journal-title":"Front Immunol"},{"key":"1986_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1478-811X-9-25","volume":"9","author":"A M\u00fcller","year":"2011","unstructured":"M\u00fcller A, Oertli M, Arnold IC. H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to Establish persistent infection. Cell Commun Signal. 2011;9:25.","journal-title":"Cell Commun Signal"},{"key":"1986_CR36","doi-asserted-by":"publisher","first-page":"981328","DOI":"10.1155\/2015\/981328","volume":"2015","author":"T Larussa","year":"2015","unstructured":"Larussa T, Leone I, Suraci E, Imeneo M, Luzza F. Helicobacter pylori and T helper cells: mechanisms of immune escape and tolerance. J Immunol Res. 2015;2015:981328.","journal-title":"J Immunol Res"},{"key":"1986_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000519413","volume":"103","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2021;103:62\u20138.","journal-title":"Digestion"},{"key":"1986_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","volume":"18","author":"E Tshibangu-Kabamba","year":"2021","unstructured":"Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance \u2014 from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18:613\u201329.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1986_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bpg.2006.11.001","volume":"21","author":"K Wolle","year":"2007","unstructured":"Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21:315\u201324.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1986_CR40","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.3748\/wjg.14.7361","volume":"14","author":"AC Ford","year":"2008","unstructured":"Ford AC, Malfertheiner P, Gigu\u00e8re M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol WJG. 2008;14:7361\u201370.","journal-title":"World J Gastroenterol WJG"},{"key":"1986_CR41","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v24.i40.4548","volume":"24","author":"T-F Lin","year":"2018","unstructured":"Lin T-F, Hsu P-I. Second-line rescue treatment of Helicobacter pylori infection: where are we now? World J Gastroenterol. 2018;24:4548\u201353.","journal-title":"World J Gastroenterol"},{"key":"1986_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1523-5378.2010.00774.x","volume":"15","author":"A O\u2019Connor","year":"2010","unstructured":"O\u2019Connor A, Gisbert JP, McNamara D, O\u2019Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15:46\u201352.","journal-title":"Helicobacter"},{"key":"1986_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/QCO.0000000000000396","volume":"30","author":"C Alba","year":"2017","unstructured":"Alba C, Blanco A, Alarc\u00f3n T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;30:489\u201397.","journal-title":"Curr Opin Infect Dis"},{"key":"1986_CR44","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/microorganisms9122502","volume":"9","author":"YY Cheok","year":"2021","unstructured":"Cheok YY, Lee CYQ, Cheong HC, Vadivelu J, Looi CY, Abdullah S, et al. An overview of Helicobacter pylori survival tactics in the hostile human stomach environment. Microorganisms. 2021;9:2502.","journal-title":"Microorganisms"},{"key":"1986_CR45","unstructured":"Comparison of Treatment Regimens for Helicobacter pylori Infection | AAFP [Internet]. [cited 2024 Mar 18]. Available from: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2021\/0900\/od1.html"},{"key":"1986_CR46","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C2SM06903B","volume":"8","author":"DJ McClements","year":"2012","unstructured":"McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 2012;8:1719\u201329.","journal-title":"Soft Matter"},{"key":"1986_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3748\/wjg.v28.i7.766","volume":"28","author":"S Sitkin","year":"2022","unstructured":"Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal Microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit\u2013risk approach? World J Gastroenterol. 2022;28:766\u201374.","journal-title":"World J Gastroenterol"},{"key":"1986_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/PPA.S286860","volume":"15","author":"H Zheng","year":"2021","unstructured":"Zheng H, Xie Q, Zhan M, Jin C, Li Q. Cost\u2013effectiveness analysis of Helicobacter pylori eradication therapy in First-Degree relatives of patients with gastric cancer. Patient Prefer Adherence. 2021;15:77\u201385.","journal-title":"Patient Prefer Adherence"},{"key":"1986_CR49","doi-asserted-by":"publisher","unstructured":"Narendrakumar L, Chakraborty M, Kumari S, Paul D, Das B. \u03b2-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward. Front Microbiol [Internet]. 2023 [cited 2024 May 15];13. Available from: https:\/\/www.frontiersin.org\/journals\/microbiology\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2022.1092556\/full","DOI":"10.3389\/fmicb.2022.1092556\/full"},{"key":"1986_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","volume":"32","author":"E Sauvage","year":"2008","unstructured":"Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32:234\u201358.","journal-title":"FEMS Microbiol Rev"},{"key":"1986_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/2141-9248.105671","volume":"2","author":"P Ughachukwu","year":"2012","unstructured":"Ughachukwu P, Unekwe P. Efflux Pump-Mediated resistance in chemotherapy. Ann Med Health Sci Res. 2012;2:191\u20138.","journal-title":"Ann Med Health Sci Res"},{"key":"1986_CR52","doi-asserted-by":"publisher","unstructured":"Choi U, Lee C-R. Distinct Roles of Outer Membrane Porins in Antibiotic Resistance and Membrane Integrity in Escherichia coli. Front Microbiol [Internet]. 2019 [cited 2024 May 15];10. Available from: https:\/\/www.frontiersin.org\/journals\/microbiology\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2019.00953\/full","DOI":"10.3389\/fmicb.2019.00953\/full"},{"key":"1986_CR53","unstructured":"Plasmids and the Spread. of Antibiotic Resistance Genes [Internet]. [cited 2024 May 15]. Available from: https:\/\/asm.org\/articles\/2023\/january\/plasmids-and-the-spread-of-antibiotic-resistance-g"},{"key":"1986_CR54","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1365-2958.2007.05975.x","volume":"66","author":"S Zaman","year":"2007","unstructured":"Zaman S, Fitzpatrick M, Lindahl L, Zengel J. Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol Microbiol. 2007;66:1039\u201350.","journal-title":"Mol Microbiol"},{"key":"1986_CR55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1016-8478(23)13537-0","volume":"9","author":"HJ Jin","year":"1999","unstructured":"Jin HJ. ermSF, a ribosomal RNA adenine N6-methyltransferase gene from streptomyces fradiae, confers MLS (macrolide-lincosamide-streptogramin B) resistance to E. coli when it is expressed. Mol Cells. 1999;9:252\u20137.","journal-title":"Mol Cells"},{"key":"1986_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/1568005043340777","volume":"4","author":"G Maravi\u0107","year":"2004","unstructured":"Maravi\u0107 G. Macrolide resistance based on the Erm-mediated rRNA methylation. Curr Drug Targets Infect Disord. 2004;4:193\u2013202.","journal-title":"Curr Drug Targets Infect Disord"},{"key":"1986_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s101560050011","volume":"5","author":"Y Nakajima","year":"1999","unstructured":"Nakajima Y. Mechanisms of bacterial resistance to macrolide antibiotics. J Infect Chemother Off J Jpn Soc Chemother. 1999;5:61\u201374.","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"1986_CR58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/biology10050388","volume":"10","author":"C Thomas","year":"2021","unstructured":"Thomas C, Gwenin CD. The role of nitroreductases in resistance to nitroimidazoles. Biology. 2021;10:388.","journal-title":"Biology"},{"key":"1986_CR59","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.resmic.2010.04.003","volume":"161","author":"LS Steffens","year":"2010","unstructured":"Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR. Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole. Res Microbiol. 2010;161:346\u201354.","journal-title":"Res Microbiol"},{"key":"1986_CR60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jac\/dkx351","volume":"73","author":"SA Dingsdag","year":"2018","unstructured":"Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure\u2013cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018;73:265\u201379.","journal-title":"J Antimicrob Chemother"},{"key":"1986_CR61","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/ncomms2470","volume":"4","author":"W Li","year":"2013","unstructured":"Li W, Atkinson GC, Thakor NS, Allas \u00dc, Lu C, Chan K-Y, et al. Mechanism of Tetracycline resistance by ribosomal protection protein Tet(O). Nat Commun. 2013;4:1477.","journal-title":"Nat Commun"},{"key":"1986_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0014-5793(95)00455-I","volume":"365","author":"A Yamaguchi","year":"1995","unstructured":"Yamaguchi A, Shiina Y, Fujihira E, Sawai T, Noguchi N, Sasatsu M. The Tetracycline efflux protein encoded by the tet(K) gene from Staphylococcus aureus is a metal-tetracycline\/H\u2009+\u2009antiporter. FEBS Lett. 1995;365:193\u20137.","journal-title":"FEBS Lett"},{"key":"1986_CR63","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1128\/AAC.42.7.1702","volume":"42","author":"JI Ross","year":"1998","unstructured":"Ross JI, Eady EA, Cove JH, Cunliffe WJ. 16S rRNA mutation associated with Tetracycline resistance in a Gram-Positive bacterium. Antimicrob Agents Chemother. 1998;42:1702\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1986_CR64","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1034\/j.1600-0463.2002.1100909.x","volume":"110","author":"E Lindb\u00e4ck","year":"2002","unstructured":"Lindb\u00e4ck E, Rahman M, Jalal S, Wretlind B. Mutations in gyrA, gyrB, parC, and ParE in quinolone-resistant strains of neisseria gonorrhoeae. APMIS Acta Pathol Microbiol Immunol Scand. 2002;110:651\u20137.","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"key":"1986_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/9780470920541.ch3","volume":"77","author":"MD Routh","year":"2011","unstructured":"Routh MD, Zalucki Y, Su C-C, Long F, Zhang Q, Shafer WM, et al. Efflux pumps of the resistance-nodulation-division family: A perspective of their structure, function and regulation in gram-negative bacteria. Adv Enzymol Relat Areas Mol Biol. 2011;77:109\u201346.","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"1986_CR66","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1128\/CMR.00016-09","volume":"22","author":"J Strahilevitz","year":"2009","unstructured":"Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-Mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev. 2009;22:664\u201389.","journal-title":"Clin Microbiol Rev"},{"key":"1986_CR67","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1128\/AAC.06077-11","volume":"56","author":"CJ Kristich","year":"2012","unstructured":"Kristich CJ, Little JL. Mutations in the \u03b2 subunit of RNA polymerase alter intrinsic cephalosporin resistance in enterococci. Antimicrob Agents Chemother. 2012;56:2022\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1986_CR68","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/ijerph120201487","volume":"12","author":"JL Andersen","year":"2015","unstructured":"Andersen JL, He G-X, Kakarla P, KC R, Kumar S, Lakra WS, et al. Multidrug efflux pumps from Enterobacteriaceae, vibrio cholerae and Staphylococcus aureus bacterial food pathogens. Int J Environ Res Public Health. 2015;12:1487\u2013547.","journal-title":"Int J Environ Res Public Health"},{"key":"1986_CR69","first-page":"59","volume":"21","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Saier MH Jr. Transposon-Mediated adaptive and directed mutations and their potential evolutionary benefits. J Mol Microbiol Biotechnol. 2012;21:59\u201370.","journal-title":"J Mol Microbiol Biotechnol"},{"key":"1986_CR70","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1128\/jb.176.11.3257-3268.1994","volume":"176","author":"P R\u00e5dstr\u00f6m","year":"1994","unstructured":"R\u00e5dstr\u00f6m P, Sk\u00f6ld O, Swedberg G, Flensburg J, Roy PH, Sundstr\u00f6m L. Transposon Tn5090 of plasmid R751, which carries an integron, is related to Tn7, Mu, and the retroelements. J Bacteriol. 1994;176:3257\u201368.","journal-title":"J Bacteriol"},{"key":"1986_CR71","doi-asserted-by":"publisher","first-page":"162199","DOI":"10.1016\/j.scitotenv.2023.162199","volume":"872","author":"A Pacholak","year":"2023","unstructured":"Pacholak A, \u017bur-Pi\u0144ska J, Pi\u0144ski A, Nguyen QA, Ligaj M, Luczak M, et al. Potential negative effect of long-term exposure to nitrofurans on bacteria isolated from wastewater. Sci Total Environ. 2023;872:162199.","journal-title":"Sci Total Environ"},{"key":"1986_CR72","doi-asserted-by":"publisher","first-page":"001333","DOI":"10.1099\/mic.0.001333","volume":"169","author":"A Gaurav","year":"2023","unstructured":"Gaurav A, Bakht P, Saini M, Pandey S, Pathania R. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology. 2023;169:001333.","journal-title":"Microbiology"},{"key":"1986_CR73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/1040841X.2021.1895721","volume":"47","author":"MPC de Souza","year":"2021","unstructured":"de Souza MPC, de Camargo BAF, Sp\u00f3sito L, Fortunato GC, Carvalho GC, Marena GD, et al. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections. Crit Rev Microbiol. 2021;47:435\u201360.","journal-title":"Crit Rev Microbiol"},{"key":"1986_CR74","doi-asserted-by":"crossref","unstructured":"Makabenta JMV, Nabawy A, Li C-H, Schmidt-Malan S, Patel R, Rotello VM. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol [Internet]. 2021 [cited 2023 Jun 8];19:23\u201336. Available from: https:\/\/www.nature.com\/articles\/s41579-020-0420-1","DOI":"10.1038\/s41579-020-0420-1"},{"key":"1986_CR75","doi-asserted-by":"crossref","unstructured":"Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Controlled Release [Internet]. 2014 [cited 2023 May 25];190:607\u201323. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168365914002661","DOI":"10.1016\/j.jconrel.2014.03.055"},{"key":"1986_CR76","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/IJN.S405052","volume":"18","author":"X Yin","year":"2023","unstructured":"Yin X, Lai Y, Du Y, Zhang T, Gao J, Li Z. Metal-Based nanoparticles: A prospective strategy for Helicobacter pylori treatment. Int J Nanomed. 2023;18:2413\u201329.","journal-title":"Int J Nanomed"},{"key":"1986_CR77","doi-asserted-by":"crossref","unstructured":"Gupta A, Mumtaz S, Li C-H, Hussain I, Rotello VM. Combatting antibiotic-resistant bacteria using nanomaterials. Chem Soc Rev [Internet]. 2019 [cited 2023 Jun 8];48:415\u201327. Available from: https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2019\/cs\/c7cs00748e","DOI":"10.1039\/C7CS00748E"},{"key":"1986_CR78","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14787210.2019.1677464","volume":"17","author":"T Safarov","year":"2019","unstructured":"Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter pylori. Expert Rev Anti Infect Ther. 2019;17:829\u201340.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1986_CR79","doi-asserted-by":"crossref","unstructured":"Ways M, Lau TM, Khutoryanskiy WM. VV. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers [Internet]. 2018 [cited 2023 Jun 7];10:267. Available from: https:\/\/www.mdpi.com\/2073-4360\/10\/3\/267.","DOI":"10.3390\/polym10030267"},{"key":"1986_CR80","doi-asserted-by":"crossref","unstructured":"Lin Y-H, Chang C-H, Wu Y-S, Hsu Y-M, Chiou S-F, Chen Y-J. Development of pH-responsive chitosan\/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials [Internet]. 2009 [cited 2023 May 23];30:3332\u201342. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S014296120900221X","DOI":"10.1016\/j.biomaterials.2009.02.036"},{"key":"1986_CR81","doi-asserted-by":"crossref","unstructured":"Lin Y-H, Chiou S-F, Lai C-H, Tsai S-C, Chou C-W, Peng S-F et al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Biochem [Internet]. 2012 [cited 2023 Jun 2];47:1469\u201378. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1359511312002243","DOI":"10.1016\/j.procbio.2012.05.019"},{"key":"1986_CR82","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/21691401.2018.1477788","volume":"46","author":"IA de Lima","year":"2018","unstructured":"de Lima IA, Khalil NM, Tominaga TT, Lechanteur A, Sarmento B, Mainardes RM. Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid. Artif Cells Nanomed Biotechnol. 2018;46:993\u20131002.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1986_CR83","doi-asserted-by":"crossref","unstructured":"Zhu X, Su T, Wang S, Zhou H, Shi W. New Advances in Nano-Drug Delivery Systems: Helicobacter pylori and Gastric Cancer. Front Oncol [Internet]. 2022 [cited 2023 May 23];12:834934. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9127958\/","DOI":"10.3389\/fonc.2022.834934"},{"key":"1986_CR84","doi-asserted-by":"publisher","unstructured":"Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Rev Anti Infect Ther [Internet]. 2019 [cited 2023 May 23];17:829\u201340. Available from: https:\/\/doi.org\/10.1080\/14787210.2019.1677464","DOI":"10.1080\/14787210.2019.1677464"},{"key":"1986_CR85","doi-asserted-by":"crossref","unstructured":"Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes [Internet]. 2022 [cited 2024 Feb 1];14. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9467593\/","DOI":"10.1080\/19490976.2022.2120747"},{"key":"1986_CR86","doi-asserted-by":"publisher","first-page":"834934","DOI":"10.3389\/fonc.2022.834934","volume":"12","author":"X Zhu","year":"2022","unstructured":"Zhu X, Su T, Wang S, Zhou H, Shi W. New advances in Nano-Drug delivery systems: Helicobacter pylori and gastric cancer. Front Oncol. 2022;12:834934.","journal-title":"Front Oncol"},{"key":"1986_CR87","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.2147\/IJN.S512066","volume":"20","author":"F Meng","year":"2025","unstructured":"Meng F, Yang L, Ji M, Zhu S, Tao H, Wang G. Nanomaterials: A prospective strategy for Biofilm-Forming\u2009<\u2009em\u2009>\u2009Helicobacter pylori\u2009Treatment. Int J Nanomed. 2025;20:5209\u201329.","journal-title":"Int J Nanomed"},{"key":"1986_CR88","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1039\/D4RA07886A","volume":"15","author":"SA Raza Shah","year":"2025","unstructured":"Raza Shah SA, Mumtaz M, Sharif S, Mustafa I, Nayila I. Helicobacter pylori and gastric cancer: current insights and nanoparticle-based interventions. RSC Adv. 2025;15:5558\u201370.","journal-title":"RSC Adv"},{"key":"1986_CR89","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/pharmaceutics16091123","volume":"16","author":"MI Alam","year":"2024","unstructured":"Alam MI, Paget T, Moosa NY, Alghurairy H, Elkordy AA. Liposomal drug delivery against Helicobacter pylori using Furazolidone and N-Acetyl cysteine in augmented therapy. Pharmaceutics. 2024;16:1123.","journal-title":"Pharmaceutics"},{"key":"1986_CR90","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejpb.2018.02.030","volume":"127","author":"CL Seabra","year":"2018","unstructured":"Seabra CL, Nunes C, Br\u00e1s M, Gomez-Lazaro M, Reis CA, Gon\u00e7alves IC, et al. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota. Eur J Pharm Biopharm. 2018;127:378\u201386.","journal-title":"Eur J Pharm Biopharm"},{"key":"1986_CR91","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1039\/D1TB02038B","volume":"9","author":"Y Qin","year":"2021","unstructured":"Qin Y, Lao Y-H, Wang H, Zhang J, Yi K, Chen Z, et al. Combatting Helicobacter pylori with oral nanomedicines. J Mater Chem B. 2021;9:9826\u201338.","journal-title":"J Mater Chem B"},{"key":"1986_CR92","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-024-01068-9","volume":"31","author":"R Chitas","year":"2024","unstructured":"Chitas R, Fonseca DR, Parreira P, Martins MCL. Targeted nanotherapeutics for the treatment of Helicobacter pylori infection. J Biomed Sci. 2024;31:78.","journal-title":"J Biomed Sci"},{"key":"1986_CR93","doi-asserted-by":"publisher","first-page":"16486","DOI":"10.1039\/C6NR05551F","volume":"8","author":"Y Ping","year":"2016","unstructured":"Ping Y, Hu X, Yao Q, Hu Q, Amini S, Miserez A, et al. Engineering bioinspired bacteria-adhesive clay nanoparticles with a membrane-disruptive property for the treatment of Helicobacter pylori infection. Nanoscale. 2016;8:16486\u201398.","journal-title":"Nanoscale"},{"key":"1986_CR94","doi-asserted-by":"publisher","first-page":"102223","DOI":"10.1016\/j.genrep.2025.102223","volume":"39","author":"Z Ebrahimi","year":"2025","unstructured":"Ebrahimi Z, Hamid H, Salari P, Beyrami M, Binabaj MM. The effects of nanoparticle based drugs on Helicobacter pylori infection and gastric cancer. Gene Rep. 2025;39:102223.","journal-title":"Gene Rep"},{"key":"1986_CR95","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jconrel.2019.02.039","volume":"300","author":"P Li","year":"2019","unstructured":"Li P, Chen X, Shen Y, Li H, Zou Y, Yuan G, et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Controlled Release. 2019;300:52\u201363.","journal-title":"J Controlled Release"},{"key":"1986_CR96","doi-asserted-by":"publisher","first-page":"21693","DOI":"10.1038\/s41598-024-65762-2","volume":"14","author":"AAS Aborabu","year":"2024","unstructured":"Aborabu AAS, Tayel AA, Assas M, Moussa SH, Alalawy AI, Almutairi FM, et al. Anti-Helicobacter pylori activity of nanocomposites from chitosan\/broccoli mucilage\/selenium nanoparticles. Sci Rep. 2024;14:21693.","journal-title":"Sci Rep"},{"key":"1986_CR97","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41467-024-45156-8","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu T, Chai S, Li M, Chen X, Xie Y, Zhao Z, et al. A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota. Nat Commun. 2024;15:844.","journal-title":"Nat Commun"},{"key":"1986_CR98","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1039\/C5SM02958A","volume":"12","author":"A Gupta","year":"2016","unstructured":"Gupta A, Burak Eral H, Alan Hatton T, Doyle S. Nanoemulsions: formation, properties and applications. Soft Matter. 2016;12:2826\u201341.","journal-title":"Soft Matter"},{"key":"1986_CR99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","volume":"64","author":"RJ Wilson","year":"2022","unstructured":"Wilson RJ, Li Y, Yang G, Zhao C-X. Nanoemulsions for drug delivery. Particuology. 2022;64:85\u201397.","journal-title":"Particuology"},{"key":"1986_CR100","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1039\/D1BM01537K","volume":"10","author":"CR Garcia","year":"2022","unstructured":"Garcia CR, Malik MH, Biswas S, Tam VH, Rumbaugh KP, Li W, et al. Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils. Biomater Sci. 2022;10:633\u201353.","journal-title":"Biomater Sci"},{"key":"1986_CR101","doi-asserted-by":"publisher","first-page":"100533","DOI":"10.1016\/j.colcom.2021.100533","volume":"45","author":"HH Tayeb","year":"2021","unstructured":"Tayeb HH, Felimban R, Almaghrabi S, Hasaballah N, Nanoemulsions. Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. Colloid Interface Sci Commun. 2021;45:100533.","journal-title":"Colloid Interface Sci Commun"},{"key":"1986_CR102","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cocis.2008.01.005","volume":"13","author":"JM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez JM, Gonz\u00e1lez C, Maestro A, Sol\u00e8 I, Pey CM, Nolla J. Nano-emulsions: new applications and optimization of their Preparation. Curr Opin Colloid Interface Sci. 2008;13:245\u201351.","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"1986_CR103","first-page":"72","volume":"2","author":"S Debnath","year":"2011","unstructured":"Debnath S, Satayanarayana, Kumar GV. Nanoemulsion-a method to improve the solubility of lipophilic drugs. Pharmanest. 2011;2:72\u201383.","journal-title":"Pharmanest"},{"key":"1986_CR104","doi-asserted-by":"publisher","first-page":"110936","DOI":"10.1016\/j.biopha.2020.110936","volume":"133","author":"SE Mendes Miranda","year":"2021","unstructured":"Mendes Miranda SE, de Alc\u00e2ntara Lemos J, Fernandes RS, Silva J, de O, Ottoni FM, Townsend DM, et al. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomed Pharmacother. 2021;133:110936.","journal-title":"Biomed Pharmacother"},{"key":"1986_CR105","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1021\/acsabm.3c01205","volume":"7","author":"R Tomar","year":"2024","unstructured":"Tomar R, Das SS, Balaga VKR, Tambe S, Sahoo J, Rath SK, et al. Therapeutic implications of dietary Polyphenols-Loaded nanoemulsions in cancer therapy. ACS Appl Bio Mater. 2024;7:2036\u201353.","journal-title":"ACS Appl Bio Mater"},{"key":"1986_CR106","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1039\/C9NA00710E","volume":"2","author":"G Pr\u00e9vot","year":"2020","unstructured":"Pr\u00e9vot G, Bsaibess T, Daniel J, Genevois C, Clermont G, Sasaki I, et al. Multimodal optical contrast agents as new tools for monitoring and tuning nanoemulsion internalisation into cancer cells. From live cell imaging to in vivo imaging of tumours. Nanoscale Adv. 2020;2:1590\u2013602.","journal-title":"Nanoscale Adv"},{"key":"1986_CR107","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jsps.2021.09.016","volume":"29","author":"A Tarik Alhamdany","year":"2021","unstructured":"Tarik Alhamdany A, Saeed AMH, Alaayedi M. Nanoemulsion and solid nanoemulsion for improving oral delivery of a breast cancer drug: Formulation, Evaluation, and a comparison study. Saudi Pharm J. 2021;29:1278\u201388.","journal-title":"Saudi Pharm J"},{"key":"1986_CR108","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/bioengineering9040158","volume":"9","author":"EB Souto","year":"2022","unstructured":"Souto EB, Cano A, Martins-Gomes C, Coutinho TE, Zieli\u0144ska A, Silva AM. Microemulsions and nanoemulsions in skin drug delivery. Bioengineering. 2022;9:158.","journal-title":"Bioengineering"},{"key":"1986_CR109","doi-asserted-by":"publisher","first-page":"102001","DOI":"10.1016\/j.apmt.2023.102001","volume":"35","author":"J Duarte","year":"2023","unstructured":"Duarte J, Sharma A, Sharifi E, Damiri F, Berrada M, Khan MA, et al. Topical delivery of nanoemulsions for skin cancer treatment. Appl Mater Today. 2023;35:102001.","journal-title":"Appl Mater Today"},{"key":"1986_CR110","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/app10051594","volume":"10","author":"EB Souto","year":"2020","unstructured":"Souto EB, Fernandes AR, Martins-Gomes C, Coutinho TE, Durazzo A, Lucarini M, et al. Nanomaterials for skin delivery of cosmeceuticals and pharmaceuticals. Appl Sci. 2020;10:1594.","journal-title":"Appl Sci"},{"key":"1986_CR111","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","volume":"328","author":"M Singh","year":"2020","unstructured":"Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release Off J Control Release Soc. 2020;328:895\u2013916.","journal-title":"J Control Release Off J Control Release Soc"},{"key":"1986_CR112","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4274\/tjps.galenos.2020.59319","volume":"18","author":"F DHAHIR RK, AL-NIMA AM, AL-BAZZAZ","year":"2021","unstructured":"Dhahir RK, Al-Nima AM, Al-Bazzaz F. Nanoemulsions as ophthalmic drug delivery systems. Turk J Pharm Sci. 2021;18:652\u201364.","journal-title":"Turk J Pharm Sci"},{"key":"1986_CR113","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ph14080725","volume":"14","author":"IM Abdulbaqi","year":"2021","unstructured":"Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, et al. Pulmonary delivery of anticancer drugs via Lipid-Based nanocarriers for the treatment of lung cancer: an update. Pharmaceuticals. 2021;14:725.","journal-title":"Pharmaceuticals"},{"key":"1986_CR114","doi-asserted-by":"publisher","first-page":"101031","DOI":"10.1016\/j.nantod.2020.101031","volume":"36","author":"J Zhou","year":"2021","unstructured":"Zhou J, Krishnan N, Jiang Y, Fang RH, Zhang L. Nanotechnology for virus treatment. Nano Today. 2021;36:101031.","journal-title":"Nano Today"},{"key":"1986_CR115","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.2147\/IJN.S279652","volume":"15","author":"Z-L Wu","year":"2020","unstructured":"Wu Z-L, Zhao J, Xu R. Recent advances in oral Nano-Antibiotics for bacterial infection therapy. Int J Nanomed. 2020;15:9587\u2013610.","journal-title":"Int J Nanomed"},{"key":"1986_CR116","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.procbio.2012.05.019","volume":"47","author":"Y-H Lin","year":"2012","unstructured":"Lin Y-H, Chiou S-F, Lai C-H, Tsai S-C, Chou C-W, Peng S-F, et al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Biochem. 2012;47:1469\u201378.","journal-title":"Process Biochem"},{"key":"1986_CR117","doi-asserted-by":"crossref","unstructured":"Chime SA, Kenechukwu FC, Attama AA, Chime SA, Kenechukwu FC, Attama AA. Nanoemulsions \u2014 Advances in Formulation, Characterization and Applications in Drug Delivery. Appl Nanotechnol Drug Deliv [Internet]. IntechOpen; 2014 [cited 2024 Mar 6]. Available from: https:\/\/www.intechopen.com\/chapters\/47116","DOI":"10.5772\/58673"},{"key":"1986_CR118","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.7150\/thno.40318","volume":"10","author":"R Zhao","year":"2020","unstructured":"Zhao R, Du S, Liu Y, Lv C, Song Y, Chen X, et al. Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy. Theranostics. 2020;10:3594\u2013611.","journal-title":"Theranostics"},{"key":"1986_CR119","doi-asserted-by":"publisher","first-page":"104676","DOI":"10.1016\/j.jddst.2023.104676","volume":"86","author":"T Kanwal","year":"2023","unstructured":"Kanwal T, Rehman K, Saifullah S, Perveen S, Maharjan R, Yasmeen S, et al. Development of positively charged amphiphile containing self-nanoemulsifying drug delivery system for improved therapeutic efficacy of metronidazole against Helicobacter pylori. J Drug Deliv Sci Technol. 2023;86:104676.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1986_CR120","doi-asserted-by":"publisher","first-page":"135877","DOI":"10.1016\/j.foodchem.2023.135877","volume":"417","author":"SM Abdelhamid","year":"2023","unstructured":"Abdelhamid SM, Edris AE, Sadek Z. Novel approach for the Inhibition of Helicobacter pylori contamination in yogurt using selected probiotics combined with Eugenol and cinnamaldehyde nanoemulsions. Food Chem. 2023;417:135877.","journal-title":"Food Chem"},{"key":"1986_CR121","doi-asserted-by":"publisher","unstructured":"Garg A, Karhana S, Khan MA. Nanomedicine for eradication of Helicobacter pylori: recent advances, challenges and future perspective. Future Microbiol [Internet]. 2024 [cited 2024 Mar 18]; Available from: https:\/\/www.futuremedicine.com\/doi\/https:\/\/doi.org\/10.2217\/fmb-2023-0189","DOI":"10.2217\/fmb-2023-0189"},{"key":"1986_CR122","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/jpm13030422","volume":"13","author":"MS Popoviciu","year":"2023","unstructured":"Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 diabetes mellitus and autoimmune diseases: A critical review of the association and the application of personalized medicine. J Pers Med. 2023;13:422.","journal-title":"J Pers Med"},{"key":"1986_CR123","doi-asserted-by":"crossref","unstructured":"Loureiro AIS, Nogueira ESC, Az\u00f3ia NG, S\u00e1rria MP, Abreu AS, Shimanovich U et al. Size controlled protein nanoemulsions for active targeting of folate receptor positive cells. 2015 [cited 2024 Jun 8]; Available from: https:\/\/repositorium.sdum.uminho.pt\/handle\/1822\/37157","DOI":"10.1016\/j.colsurfb.2015.06.073"},{"key":"1986_CR124","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules26123731","volume":"26","author":"Y Shulpekova","year":"2021","unstructured":"Shulpekova Y, Nechaev V, Kardasheva S, Sedova A, Kurbatova A, Bueverova E, et al. The concept of folic acid in health and disease. Molecules. 2021;26:3731.","journal-title":"Molecules"},{"key":"1986_CR125","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/pathogens12040599","volume":"12","author":"I Imoto","year":"2023","unstructured":"Imoto I, Yasuma T, D\u2019Alessandro-Gabazza CN, Oka S, Misaki M, Horiki N, et al. Antimicrobial effects of lactoferrin against Helicobacter pylori infection. Pathogens. 2023;12:599.","journal-title":"Pathogens"},{"key":"1986_CR126","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/ph16020214","volume":"16","author":"F Guzm\u00e1n-Mej\u00eda","year":"2023","unstructured":"Guzm\u00e1n-Mej\u00eda F, God\u00ednez-Victoria M, Molotla-Torres DE, Drago-Serrano ME. Lactoferrin as a component of pharmaceutical preparations: an experimental focus. Pharmaceuticals. 2023;16:214.","journal-title":"Pharmaceuticals"},{"key":"1986_CR127","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s43088-023-00417-1","volume":"12","author":"TA Addissouky","year":"2023","unstructured":"Addissouky TA, Wang Y, El Sayed IET, Baz AE, Ali MMA, Khalil AA. Recent trends in Helicobacter pylori management: Harnessing the power of AI and other advanced approaches. Beni-Suef Univ J Basic Appl Sci. 2023;12:80.","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"1986_CR128","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10856-023-06748-w","volume":"34","author":"M Moosazadeh Moghaddam","year":"2023","unstructured":"Moosazadeh Moghaddam M, Bolouri S, Golmohammadi R, Fasihi-Ramandi M, Heiat M, Mirnejad R. Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using Concanavalin A-coated Chitosan nanoparticles. J Mater Sci Mater Med. 2023;34:44.","journal-title":"J Mater Sci Mater Med"},{"key":"1986_CR129","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/polym13081272","volume":"13","author":"AI Visan","year":"2021","unstructured":"Visan AI, Popescu-Pelin G, Socol G. Degradation behavior of polymers used as coating materials for drug Delivery\u2014A basic review. Polymers. 2021;13:1272.","journal-title":"Polymers"},{"key":"1986_CR130","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00706-019-02474-8","volume":"150","author":"M Borowska","year":"2019","unstructured":"Borowska M, Glinka M, Filipowicz N, Terebieniec A, Szarlej P, Kot-Wasik A, et al. Polymer biodegradable coatings as active substance release systems for urological applications. Monatshefte F\u00fcr Chem - Chem Mon. 2019;150:1697\u2013702.","journal-title":"Monatshefte F\u00fcr Chem - Chem Mon"},{"key":"1986_CR131","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules26195905","volume":"26","author":"S Adepu","year":"2021","unstructured":"Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26:5905.","journal-title":"Molecules"},{"key":"1986_CR132","unstructured":"Grathwohl T. Lipid Based Excipients for Modified Release [Internet]. Pharma Excip. 2020 [cited 2024 Jun 8]. Available from: https:\/\/www.pharmaexcipients.com\/news\/excipients-modified-release\/"},{"key":"1986_CR133","doi-asserted-by":"publisher","first-page":"104896","DOI":"10.1016\/j.bioorg.2021.104896","volume":"112","author":"M Sharaf","year":"2021","unstructured":"Sharaf M, Arif M, Khan S, Abdalla M, Shabana S, Chi Z, et al. Co-delivery of hesperidin and clarithromycin in a nanostructured lipid carrier for the eradication of Helicobacter pylori in vitro. Bioorg Chem. 2021;112:104896.","journal-title":"Bioorg Chem"},{"key":"1986_CR134","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s11696-021-02030-x","volume":"76","author":"R Abdul Wahab","year":"2022","unstructured":"Abdul Wahab R, Al-obaidi NG, Yahya NA, Che Marzuki NH, Mohd Bohari SP. Formulation of a stable water-in-oil nanoemulsion rich in anti-diabetic components of the roselle extract for controlled release. Chem Pap. 2022;76:2341\u201356.","journal-title":"Chem Pap"},{"key":"1986_CR135","doi-asserted-by":"publisher","unstructured":"Hazarika H, Krishnatreyya H, Chattopadhyay P, Saha A, Pathak YV, Zaman MK. Nanoemulsion Delivery of Herbal Products: Prospects and Challenges. In: Das MK, Pathak YV, editors. Nano Med Nano Saf Recent Trends Clin Evid [Internet]. Singapore: Springer; 2020 [cited 2024 Mar 19]. pp. 267\u201388. Available from: https:\/\/doi.org\/10.1007\/978-981-15-6255-6_11","DOI":"10.1007\/978-981-15-6255-6_11"},{"key":"1986_CR136","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/ijmr.IJMR_2079_17","volume":"149","author":"A Sharma","year":"2019","unstructured":"Sharma A, Gupta VK, Pathania R. Efflux pump inhibitors for bacterial pathogens: from bench to bedside. Indian J Med Res. 2019;149:129\u201345.","journal-title":"Indian J Med Res"},{"key":"1986_CR137","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/chem.201905097","volume":"26","author":"T Jiang","year":"2020","unstructured":"Jiang T, Zhang C, Sun W, Cao X, Choi G, Choy J-H, et al. Doxorubicin encapsulated in TPGS-Modified 2D-Nanodisks overcomes multidrug resistance. Chem \u2013 Eur J. 2020;26:2470\u20137.","journal-title":"Chem \u2013 Eur J"},{"key":"1986_CR138","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2217\/nnm-2022-0006","volume":"17","author":"M Juneja","year":"2022","unstructured":"Juneja M, Suthar T, Pardhi VP, Ahmad J, Jain K. Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases. Nanomed. 2022;17:793\u2013812.","journal-title":"Nanomed"},{"key":"1986_CR139","doi-asserted-by":"crossref","unstructured":"Raj S, Kesavan D, Muthusamy D, Umamaheswari N. S. Efflux pumps potential drug targets to circumvent drug Resistance \u2013 Multi drug efflux pumps of Helicobacter pylori. Mater Today Proc. 2021;45.","DOI":"10.1016\/j.matpr.2020.11.955"},{"key":"1986_CR140","doi-asserted-by":"publisher","unstructured":"Shaalan H, Azrad M, Peretz A. The effect of three urease inhibitors on H. pylori viability, urease activity and urease gene expression. Front Microbiol [Internet]. 2024 [cited 2025 Mar 25];15. Available from: https:\/\/www.frontiersin.orghttps:\/\/www.frontiersin.org\/journals\/microbiology\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2024.1464484\/full","DOI":"10.3389\/fmicb.2024.1464484\/full"},{"key":"1986_CR141","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/molecules18022135","volume":"18","author":"M Amin","year":"2013","unstructured":"Amin M, Anwar F, Naz F, Mehmood T, Saari N. Anti-Helicobacter pylori and urease Inhibition activities of some traditional medicinal plants. Molecules. 2013;18:2135\u201349.","journal-title":"Molecules"},{"key":"1986_CR142","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s10311-021-01216-9","volume":"19","author":"TJ Ashaolu","year":"2021","unstructured":"Ashaolu TJ. Nanoemulsions for health, food, and cosmetics: a review. Environ Chem Lett. 2021;19:3381\u201395.","journal-title":"Environ Chem Lett"},{"key":"1986_CR143","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11274-023-03745-7","volume":"39","author":"FM Mosallam","year":"2023","unstructured":"Mosallam FM, Bendary MM, Elshimy R, El-Batal AI. Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections. World J Microbiol Biotechnol. 2023;39:324.","journal-title":"World J Microbiol Biotechnol"},{"key":"1986_CR144","unstructured":"Zidan R, Hanna PA, El-Deen EZ, Mostafa YM, Gad S. Records of pharmaceutical and biomedical sciences. 2023."},{"key":"1986_CR145","first-page":"6640103","volume":"2023","author":"S Preeti, Sambhakar","year":"2023","unstructured":"Preeti, Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Rani C, et al. Nanoemulsion: an emerging novel technology for improving the bioavailability of drugs. Scientifica. 2023;2023:6640103.","journal-title":"Scientifica"},{"key":"1986_CR146","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3390\/antiox12101866","volume":"12","author":"A Hidalgo","year":"2023","unstructured":"Hidalgo A, Bravo D, Soto C, Maturana G, Cordero-Machuca J, Z\u00fa\u00f1iga-L\u00f3pez MC, et al. The Anti-Oxidant Curcumin solubilized as Oil-in-Water nanoemulsions or Chitosan nanocapsules effectively reduces Helicobacter pylori Growth, bacterial biofilm Formation, gastric cell adhesion and internalization. Antioxidants. 2023;12:1866.","journal-title":"Antioxidants"},{"key":"1986_CR147","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/pharmaceutics17030337","volume":"17","author":"MD Chatzidaki","year":"2025","unstructured":"Chatzidaki MD, Mitsou E. Advancements in Nanoemulsion-Based drug delivery across different administration routes. Pharmaceutics. 2025;17:337.","journal-title":"Pharmaceutics"},{"key":"1986_CR148","doi-asserted-by":"publisher","first-page":"115086","DOI":"10.1016\/j.addr.2023.115086","volume":"202","author":"S Maher","year":"2023","unstructured":"Maher S, Geoghegan C, Brayden DJ. Safety of surfactant excipients in oral drug formulations. Adv Drug Deliv Rev. 2023;202:115086.","journal-title":"Adv Drug Deliv Rev"},{"key":"1986_CR149","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1208\/s12249-008-9178-x","volume":"10","author":"A Azeem","year":"2009","unstructured":"Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech. 2009;10:69\u201376.","journal-title":"AAPS PharmSciTech"},{"key":"1986_CR150","doi-asserted-by":"publisher","first-page":"114453","DOI":"10.1016\/j.ejpb.2024.114453","volume":"203","author":"TR Meola","year":"2024","unstructured":"Meola TR, Kamath S, Elz AS, Prestidge CA, Wignall A, Joyce P. Contrasting the Pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2024;203:114453.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV"},{"key":"1986_CR151","doi-asserted-by":"publisher","first-page":"123614","DOI":"10.1016\/j.ijpharm.2023.123614","volume":"648","author":"S Subramaniam","year":"2023","unstructured":"Subramaniam S, Elz A, Wignall A, Kamath S, Ariaee A, Hunter A, et al. Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. Int J Pharm. 2023;648:123614.","journal-title":"Int J Pharm"},{"key":"1986_CR152","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/fmb-2022-0102","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang Z, Shao S-L, Xu X-H, Zhao X, Wang M-Y, Chen A, et al. Helicobacter pylori and gastric microbiota homeostasis: progress and prospects. Future Microbiol. 2023;18:137\u201357.","journal-title":"Future Microbiol"},{"key":"1986_CR153","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/toxics11040384","volume":"11","author":"Y Ma","year":"2023","unstructured":"Ma Y, Zhang J, Yu N, Shi J, Zhang Y, Chen Z, et al. Effect of nanomaterials on gut microbiota. Toxics. 2023;11:384.","journal-title":"Toxics"},{"key":"1986_CR154","first-page":"100118","volume":"3","author":"W Utembe","year":"2022","unstructured":"Utembe W, Tlotleng N, Kamng\u2019ona A. A systematic review on the effects of nanomaterials on gut microbiota. Curr Res Microb Sci. 2022;3:100118.","journal-title":"Curr Res Microb Sci"},{"key":"1986_CR155","doi-asserted-by":"crossref","unstructured":"Wani TA, Masoodi FA, Jafari SM, McClements DJ. Chapter 19 - Safety of Nanoemulsions and Their Regulatory Status. In: Jafari SM, McClements DJ, editors. Nanoemulsions [Internet]. Academic Press; 2018 [cited 2025 Aug 7]. pp. 613\u201328. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128118382000199","DOI":"10.1016\/B978-0-12-811838-2.00019-9"},{"key":"1986_CR156","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1016\/j.apsb.2024.06.015","volume":"14","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Luo S, Xu M, He Q, Xie J, Wu J, et al. Transepithelial transport of nanoparticles in oral drug delivery: from the perspective of surface and holistic property modulation. Acta Pharm Sin B. 2024;14:3876\u2013900.","journal-title":"Acta Pharm Sin B"},{"key":"1986_CR157","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/pt050232","volume":"5","author":"RB Umamaheshwari","year":"2004","unstructured":"Umamaheshwari RB, Ramteke S, Jain NK. Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model. AAPS PharmSciTech. 2004;5:60\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"1986_CR158","unstructured":"Mestre A, Sathiya Narayanan R, Rivas D, John J, Abdulqader MA, Khanna T et al. Role of probiotics in the management of Helicobacter pylori. Cureus 14:e26463."},{"key":"1986_CR159","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1021\/bm4018484","volume":"15","author":"F Liu","year":"2014","unstructured":"Liu F, Lin S, Zhang Z, Hu J, Liu G, Tu Y, et al. pH-Responsive nanoemulsions for controlled drug release. Biomacromolecules. 2014;15:968\u201377.","journal-title":"Biomacromolecules"},{"key":"1986_CR160","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220\u201330.","journal-title":"Nature"},{"key":"1986_CR161","first-page":"101314","volume":"31","author":"S Lopez-Escalera","year":"2022","unstructured":"Lopez-Escalera S, Wellejus A. Evaluation of Caco-2 and human intestinal epithelial cells as in vitro models of colonic and small intestinal integrity. Biochem Biophys Rep. 2022;31:101314.","journal-title":"Biochem Biophys Rep"},{"key":"1986_CR162","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bbrc.2017.09.060","volume":"493","author":"LTC Tran","year":"2017","unstructured":"Tran LTC, Gueutin C, Frebourg G, Burucoa C, Faivre V. Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: protection and synergy. Biochem Biophys Res Commun. 2017;493:146\u201351.","journal-title":"Biochem Biophys Res Commun"},{"key":"1986_CR163","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11051-025-06227-z","volume":"27","author":"M Moradialvand","year":"2025","unstructured":"Moradialvand M, Saniee P, McClements DJ, Rafati H. Enhanced antimicrobial activity of cinnamomum zeylanicum essential oil nanoemulsions against Helicobacter pylori: a microfluidic-based assessment. J Nanoparticle Res. 2025;27:27.","journal-title":"J Nanoparticle Res"},{"key":"1986_CR164","doi-asserted-by":"publisher","first-page":"e13110","DOI":"10.1111\/hel.13110","volume":"29","author":"MM Bendary","year":"2024","unstructured":"Bendary MM, Elmanakhly AR, Mosallam FM, Alblwi NAN, Mosbah RA, Alshareef WA, et al. Boosting the Anti-Helicobacter efficacy of Azithromycin through natural compounds: insights from in Vitro, in Vivo, Histopathological, and molecular Docking investigations. Helicobacter. 2024;29:e13110.","journal-title":"Helicobacter"},{"key":"1986_CR165","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-019-0441-y","volume":"17","author":"Y Yang","year":"2019","unstructured":"Yang Y, Chen L, Sun H, Guo H, Song Z, You Y, et al. Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. J Nanobiotechnol. 2019;17:6.","journal-title":"J Nanobiotechnol"},{"key":"1986_CR166","doi-asserted-by":"publisher","first-page":"136404","DOI":"10.1016\/j.ijbiomac.2024.136404","volume":"281","author":"D Cai","year":"2024","unstructured":"Cai D, Ye Y, Song J, Liu S, Zeng X, Zhu B, et al. A chitosan-modified tea tree oil self-nanoemulsion improves antibacterial effects in vivo and in vitro and promotes wound healing by influencing metabolic processes against multidrug-resistant bacterial infections. Int J Biol Macromol. 2024;281:136404.","journal-title":"Int J Biol Macromol"},{"key":"1986_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2018.12.032","volume":"233","author":"L Sp\u00f3sito","year":"2019","unstructured":"Sp\u00f3sito L, Oda FB, Vieira JH, Carvalho FA, dos Santos Ramos MA, de Castro RC, et al. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. J Ethnopharmacol. 2019;233:1\u201312.","journal-title":"J Ethnopharmacol"},{"key":"1986_CR168","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1021\/acsabm.9b00523","volume":"2","author":"B Menchicchi","year":"2019","unstructured":"Menchicchi B, Savvaidou E, Th\u00f6le C, Hensel A, Goycoolea FM. Low-Molecular-Weight dextran sulfate nanocapsules inhibit the adhesion of Helicobacter pylori to gastric cells. ACS Appl Bio Mater. 2019;2:4777\u201389.","journal-title":"ACS Appl Bio Mater"},{"key":"1986_CR169","doi-asserted-by":"publisher","first-page":"136","DOI":"10.21776\/ub.biotropika.2019.007.03.7","volume":"7","author":"YA Prasetya","year":"2019","unstructured":"Prasetya YA, Nisyak K, Amanda ER. Aktivitas Antibakteri Nanoemulsi Minyak Lengkuas (Alpinia Galanga L. Willd) Dalam Menghambat Pertumbuhan Helicobacter pylori. Biotropika J Trop Biol. 2019;7:136\u201342.","journal-title":"Biotropika J Trop Biol"},{"key":"1986_CR170","doi-asserted-by":"publisher","first-page":"e268293","DOI":"10.1155\/2014\/268293","volume":"2014","author":"S Vatsraj","year":"2014","unstructured":"Vatsraj S, Chauhan K, Pathak H. Formulation of a novel nanoemulsion system for enhanced solubility of a sparingly water soluble Antibiotic, clarithromycin. J Nanosci. 2014;2014:e268293.","journal-title":"J Nanosci"},{"key":"1986_CR171","doi-asserted-by":"publisher","first-page":"155932582110136","DOI":"10.1177\/15593258211013655","volume":"19","author":"MF Radwan","year":"2021","unstructured":"Radwan MF, El-Moselhy MA, Alarif WM, Orif M, Alruwaili NK, Alhakamy NA. Optimization of Thymoquinone-Loaded Self-Nanoemulsion for management of Indomethacin-Induced ulcer. Dose-Response. 2021;19:15593258211013655.","journal-title":"Dose-Response"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01986-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:02:35Z","timestamp":1765148555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01986-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01986-7","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to the journal\u2019s policy and provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}